Suchirayu owns a state-of-the-art multi-speciality hospital in Hubli with an operational capacity of 110 beds and a potential to scale up to 250 beds
Dicerna develops RNAi-based therapies to selectively silence genes that cause or contribute to disease
Viyash has ten manufacturing facilities in India with a combined capacity of 2000 KL as well as one formulation facility in the US, and is now one of India’s leading mid-tier integrated API and formulation players
The consideration for the acquisition is US $ 2.25 million
Strides Pharma Science has reported consolidated financial results for the period ended September 30, 2021
The company has operations in North America, Asia, and Europe,
Expertise in exosomes isolation and characterization will drive innovation in this field
The acquisition expands Takeda’s immuno-oncology and innate immune cell therapy portfolio with novel platforms leveraging T cells for the potential treatment of solid tumours and haematological malignancies
Gini Health works in the domain of personalised healthcare
The combined entity will have 12 hospitals with 3,666 beds
Subscribe To Our Newsletter & Stay Updated
